lasix classification The main exclusion criteria were the following previous denosumab or ZA exposure or any aromatase inhibitor use during the 3 months; non healed or planned surgery; chemotherapy or endocrine therapy for other diseases; active metabolic bone disease; undergoing castration; recurrence and metastasis before SSEs; use of medication that affects bone metabolism; renal deterioration during treatment; other primary tumours or advanced cancer; discontinuation or interruption of denosumab or ZA treatment; unable to complete surveys; life expectancy
lasix classification The main exclusion criteria were the following previous denosumab or ZA exposure or any aromatase inhibitor use during the 3 months; non healed or planned surgery; chemotherapy or endocrine therapy for other diseases; active metabolic bone disease; undergoing castration; recurrence and metastasis before SSEs; use of medication that affects bone metabolism; renal deterioration during treatment; other primary tumours or advanced cancer; discontinuation or interruption of denosumab or ZA treatment; unable to complete surveys; life expectancy